Company intelligence / Profile preview

IMAC Holdings

Franklin, Tennessee, United Statesapple.com ↗

Ownership: Public · BACK
Employees: ~15
Development stage: Phase 1

Overview

IMAC Holdings provides a commercialized RPPA proteomics platform supporting oncology clinical decision-making and drug development. Its Ignite Proteomics subsidiary has launched a multi-protein test initially focused on breast cancer. Through its majority stake in BioFirma, it is developing NeoCyte, an umbilical cord-derived mononuclear cell product intended for regenerative medicine applications. The company also operates outpatient clinics offering orthopedic and minimally invasive therapies.

Therapeutic areas: OncologyRheumatology
Modalities: Protein analysis platform (Reverse Phase Protein Array)Cell therapy (via BioFirma/NeoCyte umbilical cord-derived mononuclear cell product)
Industry: Biotech

Partnerships

None specifically disclosed with major pharma or biotech companies.

Financials

Market cap: $2.3K
Total revenue: $21.2K
Enterprise value: $3.8M

Beyond the preview

Go deeper on IMAC Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMAC Holdings.

Explore the full profile